Case Study: Emerging Biotech Company achieves high-quality imaging data and on-track study milestones with Perceptive

Achieving High Quality Imaging Assessments with Calyx in Rescue Cases

The Emerging Biotech Company, developing novel therapies for rare diseases, turned to Perceptive after previous centralized imaging providers failed to deliver reliable imaging and operational support. They required high‑quality MRI and TCD/TCDi imaging—both qualitative and quantitative—to support study eligibility and primary endpoints but were hindered by convoluted acquisition guidelines, poor site qualification, weak site communication, and insufficient independent review rigor.

Perceptive provided medical imaging services that streamlined imaging acquisition guidelines, implemented a 3‑step site qualification process (capability assessment, staff training, test scans), fully rewrote the independent review charter, and offered ongoing scientific and medical consulting. As a result, studies are running efficiently, Perceptive is on track to deliver key imaging data to meet study milestones, and the sponsor reports significantly improved charter quality and confidence in receiving high‑quality imaging to support study endpoints.